|
1
|
Neugut AI, Jacobson JS, Suh S, Mukherjee R
and Arber N: The epidemiology of cancer of the small bowel. Cancer
Epidemiol Biomarkers Prev. 7:243–251. 1998.PubMed/NCBI
|
|
2
|
Xiang XJ, Liu YW, Zhang L, Qiu F, Yu F,
Zhan ZY, Feng M, Yan J, Zhao JG and Xiong JP: A phase II study of
modified FOLFOX as first-line chemotherapy in advanced small bowel
adenocarcinoma. Anticancer Drugs. 23:561–566. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Overman MJ, Varadhachary GR, Kopetz S,
Adinin R, Lin E, Morris JS, Eng C, Abbruzzese JL and Wolff RA:
Phase II study of capecitabine and oxaliplatin for advanced
adenocarcinoma of the small bowel and ampulla of Vater. J Clin
Oncol. 27:2598–2603. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
McWilliams RR, Mahoney MR, Marchello BT,
Jatoi A, Krewer KD, Ames MA, Schneider DJ, Seeger GR, Mowat RB,
Alberts SR and Goetz MP: Pharmacogenetic dosing by UGT1A1 genotype
as first-line therapy for advanced small-bowel adenocarcinoma: A
North Central Cancer Treatment Group (NCCTG) trial. Clin Oncol.
30(Suppl 4): 3142012.
|
|
5
|
Gibson MK, Holcroft CA, Kvols LK and
Haller D: Phase II study of 5-fluorouracil, doxorubicin, and
mitomycin C for metastatic small bowel adenocarcinoma. Oncologist.
10:132–137. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zaanan A, Costes L, Gauthier M, Malka D,
Locher C, Mitry E, Tougeron D, Lecomte T, Gornet JM, Sobhani I, et
al: Chemotherapy of advanced small-bowel adenocarcinoma: A
multicenter AGEO study. Ann Oncol. 21:1786–1793. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tsushima T, Taguri M, Honma Y, Takahashi
H, Ueda S, Nishina T, Kawai H, Kato S, Suenaga M, Tamura F, et al:
Multicenter retrospective study of 132 patients with unresectable
small bowel adenocarcinoma treated with chemotherapy. Oncologist.
17:1163–1170. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fishman PN, Pond GR, Moore MJ, Oza A,
Burkes RL, Siu LL, Feld R, Gallinger S, Greig P and Knox JJ:
Natural history and chemotherapy effectiveness for advanced
adenocarcinoma of the small bowel: A retrospective review of 113
cases. Am J Clin Oncol. 29:225–231. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Santi DV, McHenry CS and Sommer H:
Mechanism of interaction of thymidylate synthetase with
5-fluorodeoxyuridylate. Biochemistry. 13:471–481. 1974. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Danenberg PV, Heidelberger C, Mulkins MA
and Peterson AR: The incorporation of 5-fluoro-2′-deoxyuridine into
DNA of mammalian tumor cells. Biochem Biophys Res Commun.
102:654–658. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Johnston PG, Drake JC, Trepel J and
Allegra CJ: Immunological quantitation of thymidylate synthase
using the monoclonal antibody TS 106 in 5-fluorouracil-sensitive
and -resistant human cancer cell lines. Cancer Res. 52:4306–4312.
1992.PubMed/NCBI
|
|
12
|
van Triest B, Pinedo HM, van Hensbergen Y,
Smid K, Telleman F, Schoenmakers PS, van der Wilt CL, van Laar JA,
Noordhuis P, Jansen G, et al: Thymidylate synthase level as the
main predictive parameter for sensitivity to 5-fluorouracil, but
not for folate-based thymidylate synthase inhibitors, in 13
nonselected colon cancer cell lines. Clin Cancer Res. 5:643–654.
1999.PubMed/NCBI
|
|
13
|
Leichman L, Lenz HJ, Leichman CG, Groshen
S, Danenberg K, Baranda J, Spears CP, Boswell W, Silberman H,
Ortega A, et al: Quantitation of intratumoral thymidylate synthase
expression predicts for resistance to protracted infusion of
5-fluorouracil and weekly leucovorin in disseminated colorectal
cancers: Preliminary report from an ongoing trial. Eur J Cancer.
31A:1306–1310. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Leichman CG, Lenz HJ, Leichman L,
Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M and
Danenberg PV: Quantitation of intratumoral thymidylate synthase
expression predicts for disseminated colorectal cancer response and
resistance to protracted-infusion fluorouracil and weekly
leucovorin. J Clin Oncol. 15:3223–3229. 1997.PubMed/NCBI
|
|
15
|
Liersch T, Langer C, Ghadimi BM, Kulle B,
Aust DE, Baretton GB, Schwabe W, Häusler P, Becker H and Jakob C:
Lymph node status and TS gene expression are prognostic markers in
stage II/III rectal cancer after neoadjuvant fluorouracil-based
chemoradiotherapy. J Clin Oncol. 24:4062–4068. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Horie N, Aiba H, Oguro K, Hojo H and
Takeishi K: Functional analysis and DNA polymorphism of the
tandemly repeated sequences in the 5′-terminal regulatory region of
the human gene for thymidylate synthase. Cell Struct Funct.
20:191–197. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kawakami K, Omura K, Kanehira E and
Watanabe Y: Polymorphic tandem repeats in the thymidylate synthase
gene is associated with its protein expression in human
gastrointestinal cancers. Anticancer Res. 19:3249–3252. 1999.
|
|
18
|
Mandola MV, Stoehlmacher J, Muller-Weeks
S, Cesarone G, Yu MC, Lenz HJ and Ladner RD: A novel single
nucleotide polymorphism within the 5′ tandem repeat polymorphism of
the thymidylate synthase gene abolishes USF-1 binding and alters
transcriptional activity. Cancer Res. 63:2898–2904. 2003.PubMed/NCBI
|
|
19
|
Kawakami K and Watanabe G: Identification
and functional analysis of single nucleotide polymorphism in the
tandem repeat sequence of thymidylate synthase gene. Cancer Res.
63:6004–6007. 2003.PubMed/NCBI
|
|
20
|
Marcuello E, Altés A, del Rio E, César A,
Menoyo A and Baiget M: Single nucleotide polymorphism in the 5′
tandem repeat sequences of thymidylate synthase gene predicts for
response to fluorouracil-based chemotherapy in advanced colorectal
cancer patients. Int J Cancer. 112:733–737. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fernández-Contreras ME, Sánchez-Prudencio
S, Sánchez-Hernández JJ, García de Paredes ML, Gisbert JP,
Roda-Navarro P and Gamallo C: Thymidylate synthase expression
pattern, expression level and single nucleotide polymorphism are
predictors for disease-free survival in patients of colorectal
cancer treated with 5-fluorouracil. Int J Oncol. 28:1303–1310.
2006.PubMed/NCBI
|
|
22
|
Hur H, Kang J, Kim NK, Min BS, Lee KY,
Shin SJ, Keum KC, Choi J, Kim H, Choi SH, et al: Thymidylate
synthase gene polymorphism affects the response to preoperative
5-fluorouracil chemoradiation therapy in patients with rectal
cancer. Int J Radiat Oncol Biol Phys. 81:669–676. 2011. View Article : Google Scholar
|
|
23
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van
Oosterom AT, Christian MC, et al: New guidelines to evaluate the
response to treatment in solid tumors. European Organization for
Research and Treatment of Cancer, National Cancer Institute of the
United States, National Cancer Institute of Canada. J Natl Cancer
Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Raghav K and Overman MJ: Small bowel
adenocarcinomas-existing evidence and evolving paradigms. Nat Rev
Clin Oncol. 10:534–544. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kawakami K, Salonga D, Park JM, Danenberg
KD, Uetake H, Brabender J, Omura K, Watanabe G and Danenberg PV:
Different lengths of a polymorphic repeat sequence in the
thymidylate synthase gene affect translational efficiency but not
its gene expression. Clin Cancer Res. 7:4096–4101. 2001.PubMed/NCBI
|
|
26
|
Iacopetta B, Grieu F, Joseph D and Elsaleh
H: A polymorphism in the enhancer region of the thymidylate
synthase promoter influences the survival of colorectal cancer
patients treated with 5-fluorouracil. Br J Cancer. 85:827–830.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Marsh S, McKay JA, Cassidy J and McLeod
HL: Polymorphism in the thymidylate synthase promoter enhancer
region in colorectal cancer. Int J Oncol. 19:383–386.
2001.PubMed/NCBI
|
|
28
|
Etienne MC, Chazal M, Laurent-Puig P,
Magné N, Rosty C, Formento JL, Francoual M, Formento P, Renée N,
Chamorey E, et al: Prognostic value of tumoral thymidylate synthase
and p53 in metastatic colorectal cancer patients receiving
fluorouracil-based chemotherapy: Phenotypic and genotypic analyses.
J Clin Oncol. 20:2832–2843. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tsuji T, Hidaka S, Sawai T, Nakagoe T,
Yano H, Haseba M, Komatsu H, Shindou H, Fukuoka H, Yoshinaga M, et
al: Polymorphism in the thymidylate synthase promoter enhancer
region is not an efficacious marker for tumor sensitivity to
5-fluorouracil-based oral adjuvant chemotherapy in colorectal
cancer. Clin Cancer Res. 9:3700–3704. 2003.PubMed/NCBI
|
|
30
|
Overman MJ, Pozadzides J, Kopetz S, Wen S,
Abbruzzese JL, Wolff RA and Wang H: Immunophenotype and molecular
characterisation of adenocarcinoma of the small intestine. Br J
Cancer. 102:144–150. 2010. View Article : Google Scholar :
|
|
31
|
Aparicio T, Svrcek M, Zaanan A, Beohou E,
Laforest A, Afchain P, Mitry E, Taieb J, Di Fiore F, Gornet JM, et
al: Small bowel adenocarcinoma phenotyping, a clinicobiological
prognostic study. Br J Cancer. 109:3057–3066. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nishiyama K, Yao T, Yonemasu H, Yamaguchi
K, Tanaka M and Tsuneyoshi M: Overexpression of p53 protein and
point mutation of K-ras genes in primary carcinoma of the small
intestine. Oncol Rep. 9:293–300. 2002.PubMed/NCBI
|
|
33
|
Santini D, Fratto ME, Spoto C, Russo A,
Galluzzo S, Zoccoli A, Vincenzi B and Tonini G: Cetuximab in small
bowel adenocarcinoma: A new friend? Br J Cancer. 103:1305author
reply 1306. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
De Dosso S, Molinari F, Martin V, Frattini
M and Saletti P: Molecular characterisation and cetuximab-based
treatment in a patient with refractory small bowel adenocarcinoma.
Gut. 59:1587–1588. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang YC, Xue HP, Wang ZH and Fang JY: An
integrated analysis of the association between Ts gene
polymorphisms and clinical outcome in gastric and colorectal cancer
patients treated with 5-FU-based regimens. Mol Biol Rep.
40:4637–4644. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Park CM, Lee WY, Chun HK, Cho YB, Yun HR,
Heo JS, Yun SH and Kim HC: Relationship of polymorphism of the
tandem repeat sequence in the thymidylate synthase gene and the
survival of stage III colorectal cancer patients receiving adjuvant
5-flurouracil-based chemotherapy. J Surg Oncol. 101:22–27. 2010.
View Article : Google Scholar
|
|
37
|
Aschele C, Debernardis D, Casazza S,
Antonelli G, Tunesi G, Baldo C, Lionetto R, Maley F and Sobrero A:
Immunohistochemical quantitation of thymidylate synthase expression
in colorectal cancer metastases predicts for clinical outcome to
fluorouracil-based chemotherapy. J Clin Oncol. 17:1760–1770.
1999.PubMed/NCBI
|
|
38
|
Johnston PG, Benson AB III, Catalano P,
Rao MS, O’Dwyer PJ and Allegra CJ: Thymidylate synthase protein
expression in primary colorectal cancer: Lack of correlation with
outcome and response to fluorouracil in metastatic disease sites. J
Clin Oncol. 21:815–819. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Popat S, Matakidou A and Houlston RS:
Thymidylate synthase expression and prognosis in colorectal cancer:
A systematic review and meta-analysis. J Clin Oncol. 22:529–536.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Qiu LX, Tang QY, Bai JL, Qian XP, Li RT,
Liu BR and Zheng MH: Predictive value of thymidylate synthase
expression in advanced colorectal cancer patients receiving
fluoropyrimidine-based chemotherapy: Evidence from 24 studies. Int
J Cancer. 123:2384–2389. 2008. View Article : Google Scholar : PubMed/NCBI
|
